Alex Zhavoronkov (Insilico)

'Longevi­ty as a ser­vice': In­sil­i­co spins off AI biotech that trains deep learn­ing on an­ti-ag­ing treat­ments

Since its in­cep­tion in 2014, In­sil­i­co has racked up deal af­ter deal on the promise that ar­ti­fi­cial in­tel­li­gence can has­ten drug de­vel­op­ment, tout­ing their work on dis­cov­er­ing small mol­e­cules. The biotech’s founder, Alex Zha­voronkov, has pub­lished sev­er­al sci­en­tif­ic pa­pers quan­ti­fy­ing just how im­pact­ful this tech­nol­o­gy can be.

On Tues­day, Zha­voronkov ex­tend­ed his AI ex­per­tise in­to the field of an­ti-ag­ing.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.